deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT05384249

Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis

A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Non-infectious, Intermediate-, Posterior- or Pan-uveitis

Sponsor: ACELYRIN Inc.

Conditions Uveitis
Interventions Izokibep Placebo
Updated 24 times since 2022 Last updated: Feb 20, 2025 Started: Aug 23, 2022 Primary completion: Feb 7, 2025 Completion: Feb 7, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study primary and secondary endpoints did not achieve statistical significance.

Other terminated trials from ACELYRIN Inc.

More terminations from ACELYRIN Inc.

Other Uveitis trials with similar outcome

Browse all Uveitis trials

Listed as NCT05384249, this PHASE2 trial focuses on Uveitis and remains terminated or withdrawn. Sponsored by ACELYRIN Inc., it has been updated 24 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Sep 2023 · 31 days · monthly snapshot~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Apr 2024 · 4 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Jan 2025 · 3 months · monthly snapshot~Jan 2025 – ~Feb 2025 · 31 days · monthly snapshot~Feb 2025 – ~Mar 2025 · 28 days · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Mar 2025 — Sep 2025 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Feb 2025 — Mar 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Jan 2025 — Feb 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 19 earlier versions

  1. Sep 2024 — Oct 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Jun 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Apr 2024 — Jun 2024 [monthly]

    Recruiting PHASE2

  5. Dec 2023 — Apr 2024 [monthly]

    Recruiting PHASE2

  6. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

  7. Sep 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  8. Aug 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  9. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE2

  10. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  11. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  12. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  13. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

  14. Feb 2023 — Mar 2023 [monthly]

    Recruiting PHASE2

  15. Dec 2022 — Feb 2023 [monthly]

    Recruiting PHASE2

  16. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  17. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE2

  18. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  19. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ACELYRIN Inc.
Data source: ACELYRIN Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Bakersfield, United States , Barcelona, Spain , Bellaire, United States , Berlin, Germany , Beverly Hills, United States , Bonn, Germany , Brno, Czechia , Charleston, United States , Clearwater, United States and 44 more locations